The BEDROCK Act directs the Department of Commerce to strengthen domestic biomanufacturing competitiveness by streamlining federal processes, securing supply chains, and fostering industry collaboration.
Robert Latta
Representative
OH-5
The BEDROCK Act aims to strengthen U.S. biomanufacturing by establishing a senior official within the Department of Commerce to lead efforts in enhancing domestic competitiveness and supply-chain resilience. The bill mandates regular assessments of critical supply-chain vulnerabilities, the creation of a federal commercialization process map, and the development of industry-led best practices. By coordinating federal resources and reducing regulatory barriers, the legislation seeks to secure domestic production capacity and decrease reliance on foreign adversaries.
BEDROCK Act Aims to Secure U.S. Biomanufacturing Supply Chains and Cut Federal Red Tape by 2025
The BEDROCK Act is a strategic move to shore up the American biomanufacturing industry—the folks making everything from industrial enzymes to lab-grown proteins—by treating it as a critical piece of national infrastructure. Within one year of becoming law, the Secretary of Commerce must appoint a senior official to act as a high-level fixer for the industry. This leader is tasked with identifying supply chain 'chokepoints' and 'single points of failure,' specifically looking at how much we rely on foreign adversaries for the building blocks of biotech, like bioreactors and specialized cell lines. The bill aims to turn a scattered federal approach into a streamlined roadmap for domestic production.
Mapping the Maze
One of the biggest headaches for any business, whether you're a tech startup or a local manufacturer, is figuring out which federal agency actually has the final say. Section 2 of the bill requires the Department of Commerce to create a 'Federal Commercialization Process Map.' This isn't just a list; it’s a guide designed to identify overlaps and gaps in the rules. By requiring the FDA and EPA to appoint specific points of contact, the bill tries to ensure that a company trying to bring a new bio-based material to market isn't stuck in a loop of 'call the other guy' for months. For a small business owner in this space, this could mean the difference between getting a product to market in two years versus five.
Stress-Testing the Supply Chain
The bill mandates a deep-dive assessment every two years into where our 'critical inputs' come from. We’re talking about the amino acids and microbial strains that are the ingredients for modern medicine and sustainable materials. If the Secretary finds we are too dependent on a foreign adversary for a specific industrial enzyme, they have to develop a prioritized action plan to fix it. This means identifying which U.S. factories could step up and what federal money is already available to help them expand. It’s essentially a 'buy American' strategy backed by data, intended to prevent the kind of shortages we saw during recent global supply chain meltdowns.
Protecting Trade Secrets
To get this data, the government needs companies to be honest about their vulnerabilities, which is why the bill includes specific protections for 'sensitive supply-chain information.' If a company voluntarily shares its secret sauce or its list of suppliers to help the government plan, that info is exempt from public disclosure. This is a crucial 'handshake' provision: the government gets the data it needs to protect the economy, and the private sector gets a guarantee that their competitors won't see their internal logistics. While the bill’s heavy lifting expires after five years, the goal is to have a self-sustaining, resilient domestic industry by then.